Alamar Biosciences Secures Over $50 Million in Financing and Strengthens Leadership Team

Alamar Biosciences Secures Significant Financing

Fremont, California – January 11, 2026 – Alamar Biosciences, Inc., a pioneer in precision proteomics, has successfully completed the closure of an oversubscribed convertible notes financing, adding more than $50 million to its capital. This funding round included participation from new investors such as T. Rowe Price Investment Management, Inc. and Braidwell LP, along with existing backers like Illumina Ventures and Sands Capital. This substantial financial boost will enable Alamar to accelerate its commercial objectives in precision medicine, particularly in early disease detection.

Dr. Yuling Luo, the founder and CEO of Alamar, expressed gratitude for the ongoing support from existing partners while welcoming new investors. His statement underscored the confidence these investors have in Alamar's vision and strategic direction, affirming their commitment to transform the early detection of diseases through precision proteomics. "Their belief in our mission highlights the groundbreaking potential of our efforts. This investment empowers us to drive further innovation and extend our platform's impact, enhancing the future of healthcare," Dr. Luo said.

Leadership Team Expansion

In addition to securing funding, Alamar is advancing its commitment to operational excellence by strengthening its leadership team. The company has appointed Dr. Stephen Williams, MD, Ph.D., as Chief Scientific Officer. With over 30 years of experience in precision medicine and biomarker innovation, Dr. Williams is a renowned leader previously holding significant positions at Standard BioTools and SomaLogic, as well as spending 18 years in senior roles at Pfizer. His expertise is expected to advance Alamar's scientific initiatives further.

Joining the board of directors are Rebecca Chambers and Dr. Frank Witney, both bringing extensive experience from leading roles in the life sciences and healthcare sectors. Rebecca, the current CFO at Veracyte, offers a robust background in financial leadership, while Dr. Witney, an operating partner at Ampersand Capital Partners, contributes a wealth of experience from his previous leadership roles at Affymetrix and Dionex Corporation.

Dr. Luo warmly welcomed the new appointees, stating, "I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors. Their vast expertise and varied perspectives will be invaluable as we work towards enhancing the capacity of our Precision Proteomics platform to make a significant impact on health outcomes. This is indeed an exciting chapter for Alamar."

About Alamar Biosciences

Founded as a privately held life sciences company, Alamar Biosciences focuses on harnessing precision proteomics to facilitate the earliest possible detection of diseases. Utilizing their proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is tailored to offer ultra-high sensitivity while addressing the prevalent limitations in existing technologies, thereby delivering unparalleled precision in proteomics. To learn more about their innovations and initiatives, visit alamarbio.com.